{"version":1,"type":"rich","provider_name":"Libsyn","provider_url":"https:\/\/www.libsyn.com","height":90,"width":600,"title":"Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy","description":"This is the fourth episode of our new &quot;Program on JAK Inhibitors for Atopic Dermatitis&quot; series, hosted by expert dermatologist Dr. Christopher Bunick, MD, PhD. This episode, &quot;Setting the Stage: Effective Onboarding of your AD Patients onto JAK Inhibitor Therapy&quot;, featuring expert dermatologist Dr. Ruth Ann Vleugels, MD, MPH discusses the following topics:   Identifying ideal candidates for oral JAK inhibitor therapy   Steps to initiate therapy and onboard new patients   How to manage side effects and maintain adherence to treatment   Case examples and real-world data   ","author_name":"DermDocs","author_url":"http:\/\/dermdocs.libsyn.com\/website","html":"<iframe title=\"Libsyn Player\" style=\"border: none\" src=\"\/\/html5-player.libsyn.com\/embed\/episode\/id\/32442977\/height\/90\/theme\/custom\/thumbnail\/yes\/direction\/forward\/render-playlist\/no\/custom-color\/88AA3C\/\" height=\"90\" width=\"600\" scrolling=\"no\"  allowfullscreen webkitallowfullscreen mozallowfullscreen oallowfullscreen msallowfullscreen><\/iframe>","thumbnail_url":"https:\/\/assets.libsyn.com\/secure\/content\/175724402"}